Launch Delays In U.S. Dampen Dr. Reddy's Q1 Earnings But Money Starts Flowing From GSK Deal; Analysts Confident On Future Outlook
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The first tangible benefits of the deal Dr. Reddy's Labs struck last year with GlaxoSmithKline for supply of over 100 branded formulations have become visible with the Indian company receiving $4 million from its British partner in return for moving dossiers and trademarks for nine currently marketed products in Brazil
You may also be interested in...
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India
Novartis And Quark Partner On Phase II siRNA Drug For Kidney Damage Indications
Already partnered in RNA interference with Alnylam, Novartis pays $10 million for an option to Quark's QPI-1002.